Immuneering (IMRX) Income from Continuing Operations (2020 - 2026)
Immuneering (IMRX) posted quarterly Income from Continuing Operations of 32053050.0 for Q1 2026, down 110.46% year-over-year from 306305746.53 in Q1 2025, and down 165.32% quarter-over-quarter from 12080726.0 in Q4 2025.
Immuneering (IMRX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Immuneering's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 32053050.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 110.46% year-over-year to 32053050.0; the TTM figure through Mar 2026 stood at 108670193.0 (down 45.18% YoY), while the FY2025 annual figure was 129714984.0, down 7.67% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 32053050.0, down from 12080726.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 12080726.0 in Q4 2025, with the low at 44500816.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 19379811.0 (2022), against an average of 22252255.76.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 188.98% in 2022, then surged 40.55% in 2024.
- Immuneering's Income from Continuing Operations stood at 13598653.0 in 2022, then declined by 15.75% to 15740444.0 in 2023, then declined by 16.43% to 18326461.0 in 2024, then soared by 34.08% to 12080726.0 in 2025, then tumbled by 165.32% to 32053050.0 in 2026.
- Business Quant data shows IMRX's Income from Continuing Operations at 32053050.0 in Q1 2026, 12080726.0 in Q4 2025, and 44500816.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | -33.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.13 Mn |
| Mar 31, 2026 | -32.05 Mn |
| Dec 31, 2025 | -12.08 Mn |
| Sep 30, 2025 | -44.50 Mn |
| Jun 30, 2025 | -20.04 Mn |
| Mar 31, 2025 | -15.23 Mn |
| Dec 31, 2024 | -18.33 Mn |
| Sep 30, 2024 | -20.88 Mn |
| Jun 30, 2024 | -20.42 Mn |
| Mar 31, 2024 | -14.71 Mn |
| Dec 31, 2023 | -15.74 Mn |
| Sep 30, 2023 | -25.99 Mn |
| Jun 30, 2023 | -34.34 Mn |
| Mar 31, 2023 | -14.06 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | -38.85 Mn |
| Jun 30, 2022 | -19.38 Mn |
| Mar 31, 2022 | -18.08 Mn |
| Dec 31, 2021 | -11.00 Mn |
| Sep 30, 2021 | -64.86 Mn |